Summit Therapeutics plc (SMMT): Price and Financial Metrics


Summit Therapeutics plc (SMMT): $1.06

0.01 (+0.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SMMT POWR Grades


  • Sentiment is the dimension where SMMT ranks best; there it ranks ahead of 67.34% of US stocks.
  • The strongest trend for SMMT is in Stability, which has been heading down over the past 179 days.
  • SMMT ranks lowest in Momentum; there it ranks in the 4th percentile.

SMMT Stock Summary

  • With a price/sales ratio of 147.54, Summit Therapeutics Inc has a higher such ratio than 98.18% of stocks in our set.
  • With a year-over-year growth in debt of 498.28%, Summit Therapeutics Inc's debt growth rate surpasses 97.21% of about US stocks.
  • In terms of volatility of its share price, SMMT is more volatile than 94.38% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Summit Therapeutics Inc, a group of peers worth examining would be XNCR, INBX, ANAB, ARCT, and RVMD.
  • SMMT's SEC filings can be seen here. And to visit Summit Therapeutics Inc's official web site, go to www.summitplc.com.

SMMT Valuation Summary

  • SMMT's price/sales ratio is 1262; this is 11018.94% higher than that of the median Healthcare stock.
  • Over the past 79 months, SMMT's EV/EBIT ratio has gone down 2.6.
  • SMMT's price/sales ratio has moved NA NA over the prior 79 months.

Below are key valuation metrics over time for SMMT.

Stock Date P/S P/B P/E EV/EBIT
SMMT 2021-08-31 1262.0 6.5 -10.6 -9.2
SMMT 2021-08-30 1271.5 6.5 -10.7 -9.3
SMMT 2021-08-27 1309.4 6.7 -11.0 -9.6
SMMT 2021-08-26 1281.0 6.6 -10.8 -9.4
SMMT 2021-08-25 1262.0 6.5 -10.6 -9.2
SMMT 2021-08-24 1282.6 6.6 -10.8 -9.4

SMMT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SMMT has a Quality Grade of D, ranking ahead of 7.27% of graded US stocks.
  • SMMT's asset turnover comes in at 0.006 -- ranking 406th of 682 Pharmaceutical Products stocks.
  • EDIT, SAGE, and SVRA are the stocks whose asset turnover ratios are most correlated with SMMT.

The table below shows SMMT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.006 1 -10.188
2020-12-31 0.009 1 -12.994
2019-10-31 -0.197 1 -4.153
2019-07-31 -0.198 1 -4.482
2019-04-30 0.605 1 1.189
2019-01-31 0.604 1 0.877

SMMT Price Target

For more insight on analysts targets of SMMT, see our SMMT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.50 Average Broker Recommendation 1.5 (Moderate Buy)

SMMT Stock Price Chart Interactive Chart >

Price chart for SMMT

SMMT Price/Volume Stats

Current price $1.06 52-week high $8.70
Prev. close $1.05 52-week low $1.01
Day low $1.04 Volume 83,081
Day high $1.09 Avg. volume 125,559
50-day MA $2.16 Dividend yield N/A
200-day MA $4.07 Market Cap 104.01M

Summit Therapeutics plc (SMMT) Company Bio


Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company was founded in 2003 and is based in Abingdon, England.


SMMT Latest News Stream


Event/Time News Detail
Loading, please wait...

SMMT Latest Social Stream


Loading social stream, please wait...

View Full SMMT Social Stream

Latest SMMT News From Around the Web

Below are the latest news stories about Summit Therapeutics Inc that investors may wish to consider to help them evaluate SMMT as an investment opportunity.

We Think Summit Therapeutics (NASDAQ:SMMT) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | February 24, 2022

Summit Therapeutics Announces Postponement of Its Planned Rights Offering

Cambridge, Massachusetts, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced the postponement of its previously announced rights offering to stockholders of record on February 4, 2022. The Company had previously announced topline results for its Phase III Ri-CoDIFy study evaluating ridinilazole for the treatment of and Sustained Clinical Response (“SCR”) for patients suffering from C. difficile infection ("C. diff. infection" or

Yahoo | February 9, 2022

Summit Therapeutics Announces Rights Offering

Cambridge, Massachusetts, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $0.01 (the “Common Stock”) as of the close of the market on February 4, 2022 (the “Record Date”). The Company intends to distribute to all holders of Common Stock as of the Record Date non-transferable subscript

Yahoo | January 25, 2022

Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference

Cambridge, Massachusetts, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the Company’s vision and its intended future development pathways at the 40th Annual J.P. Morgan Healthcare Conference at approximately 3:45 PM EST. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Operating Officer and a member of Summit’s Board of Directors, will provide det

Yahoo | January 10, 2022

Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference

Cambridge, Massachusetts, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it will present the Company’s vision and its intended future development pathways at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at approximately 3:45 PM EST. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Operating Officer and a member of Summit’s Board of Directors, will prov

Yahoo | January 5, 2022

Read More 'SMMT' Stories Here

SMMT Price Returns

1-mo N/A
3-mo -50.23%
6-mo -80.73%
1-year -84.53%
3-year -34.16%
5-year -90.48%
YTD -60.59%
2021 -42.77%
2020 193.75%
2019 39.13%
2018 -89.62%
2017 29.44%

Continue Researching SMMT

Here are a few links from around the web to help you further your research on Summit Therapeutics plc's stock as an investment opportunity:

Summit Therapeutics plc (SMMT) Stock Price | Nasdaq
Summit Therapeutics plc (SMMT) Stock Quote, History and News - Yahoo Finance
Summit Therapeutics plc (SMMT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7359 seconds.